Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) Q4FY26 Management Mirror - Mar-2026 Qtr
Revenue & Growth Outlook
Management continues to target revenue growth at 1.5x the Indian Pharmaceutical Market (IPM), translating to an expected growth band of 12% to 15% in the Mar'26 Qtr, consistent with the objective set in the Dec'25 Qtr to achieve 50% higher growth than the industry average. In the Sep'25 Qtr, the company initially guided for 10% or low double-digit growth for the fiscal year before formalizing the 1.5x IPM target in subsequent quarters, expecting sustainable momentum driven equally by price hikes, new product contributions, and volume expansion. [Status: Reaffirmed]
3 more themes on the ELITE plan.